{"title":"Syphilis and other sexually transmitted diseases in HIV infection.","authors":"Jeanne Marrazzo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An ongoing resurgence of syphilis and continued transmission of other common sexually transmitted diseases (STDs) in HIV-infected patients is fueled by a number of factors, including \"prevention burnout\" resulting from fatigue with long-term, safer-sex behavior, use of recretional drugs (notably methamphetamine), and false sense of security associated with HIV serosorting and elevated CD4+ cell count. Annual screening for common STDs is recommended for HIV-infected patients. Issues in syphilis and herpes simplex virus-2 (HSV-2) diagnosis and treatment are discussed. New problems are briefly reviewed, which include the increased reporting of lymphogranuloma venereum and the increased frequency of fluoroquinolone-resistant gonorrhea. The recently revised Centers for Disease Control and Prevention guidelines for treatment of syphilis, HSV-2 infection, chlamydial infection, and gonorrhea are summarized. This article summarizes a presentation on syphilis and other STDs made by Jeanne Marrazzo, MD, MPH, at the International AIDS Society-USA Continuing Medical Education course in New York, in October 2006. The original presentation is available as a Webcast at www.iasusa.org.</p>","PeriodicalId":85800,"journal":{"name":"Topics in HIV medicine : a publication of the International AIDS Society, USA","volume":"15 1","pages":"11-6"},"PeriodicalIF":0.0,"publicationDate":"2007-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26242254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hepatitis B virus treatment in HIV-infected patients.","authors":"Chloe L Thio","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hepatitis B virus (HBV) infection is common in HIV-infected persons and is associated with increased risk of liver-related morbidity and mortality. Agents available to treat HBV infection in coinfected patients include lamivudine, entecavir, emtricitabine, adefovir, peginterferon alfa, and the recently approved telbivudine. Treatment decisions should take into account a number of factors, including antiretroviral therapy status, HBV genotype, prior experience of lamivudine, and the need to avoid drug resistance in both HIV- and HBV-infected persons. This article summarizes a presentation on treatment and management of HBV infection in HIV-infected patients made by Chloe L. Thio, MD, at the 9th Annual Ryan White CARE Act Update in Washington, DC. The original presentation is available as a Webcast at www.iasusa.org.</p>","PeriodicalId":85800,"journal":{"name":"Topics in HIV medicine : a publication of the International AIDS Society, USA","volume":"14 5","pages":"170-5"},"PeriodicalIF":0.0,"publicationDate":"2006-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26500921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Immunizations for HIV-infected adults: indications, timing, and response.","authors":"David H Spach","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Vaccines routinely recommended for HIV-infected adults include those for influenza, hepatitis A virus, hepatitis B virus, pneumococcal infection, and tetanus. Responses to vaccination may be affected by CD4+ cell count and viral load. A number of live vaccines are contraindicated in the HIV-infected population. This article summarizes a presentation on immunization in HIV-infected adults made by David H. Spach, MD, at the 9th Annual Ryan White CARE Act Clinical Update in Washington, DC, in August 2006. The original presentation is available as a Webcast at www.iasusa.org.</p>","PeriodicalId":85800,"journal":{"name":"Topics in HIV medicine : a publication of the International AIDS Society, USA","volume":"14 5","pages":"154-8"},"PeriodicalIF":0.0,"publicationDate":"2006-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26500916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Renal disease and toxicities: issues for HIV care providers.","authors":"Derek M Fine","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The prevalence of renal disease is increasing in the HIV-infected population, likely reflecting increases in renal disease in the general population due to hypertension and diabetes, clustering of HIV cases in black Americans (who have higher frequency of renal risk factors), and toxicities of antiretroviral and other drugs taken by HIV-infected patients. Screening for renal function and regular follow up are recommended for all HIV-infected individuals starting at the time of HIV diagnosis. Elements of screening include quantitative risk-factor assessment and screening tests, such as urine protein quantitation and estimation of creatinine clearance and glomerular filtration rate. Diagnosis of renal dysfunction includes consideration of causative factors common in the general population as well as HIV-specific factors. This article summarizes a presentation on renal impairment in HIV disease made by Derek M. Fine, MD, at the 9th Annual Ryan White CARE Act Clinical Update in Washington, DC, in August 2006. The original presentation is available as a Webcast at www.iasusa.org.</p>","PeriodicalId":85800,"journal":{"name":"Topics in HIV medicine : a publication of the International AIDS Society, USA","volume":"14 5","pages":"164-9"},"PeriodicalIF":0.0,"publicationDate":"2006-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26500918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prioritizing primary care in HIV: comorbidity, toxicity, and demography.","authors":"Amy C Justice","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Mortality among HIV-infected patients after the first year of antiretroviral therapy has not improved in recent years. Future improvement in survival may come partly through earlier diagnosis and institution of treatment and by maximizing treatment adherence. However, outcomes in HIV disease are also influenced today by long-term treatment toxicities, non-HIV-specific comorbid conditions, and comorbid behaviors. Primary care efforts to improve outcomes should be focused on health behaviors (eg, adherence, elimination of substance abuse, diet, and exercise) and effective management of conditions such as hypertension and depression, since successful intervention in these areas reduces risk of a variety of conditions associated with mortality in HIV disease. Issues in prioritizing primary care in HIV disease were discussed by Amy C. Justice, MD, PhD, at the 9th Annual Ryan White CARE Act Clinical Update in Washington, DC. The original presentation is available as a Webcast at www.iasusa.org.</p>","PeriodicalId":85800,"journal":{"name":"Topics in HIV medicine : a publication of the International AIDS Society, USA","volume":"14 5","pages":"159-63"},"PeriodicalIF":0.0,"publicationDate":"2006-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26500439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Nucleoside analogue reverse transcriptase inhibitor options: a re-examination of the class.","authors":"Scott M Hammer","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The main options for dual nucleoside (or nucleotide) analogue reverse transcriptase inhibitors (nRTIs) as a component of initial antiretroviral therapy regimens are tenofovir/emtricitabine, zidovudine/lamivudine, and abacavir/lamivudine as fixed-dose combinations. Resistance to nRTIs can limit usefulness of many of the drugs in the class. Investigation of triple nRTI regimens has shown that zidovudine/lamivudine/abacavir does not provide benefits compared with dual nRTIs plus efavirenz and that others (tenofovir/lamivudine/abacavir and didanosine/lamivudine/abacavir) are associated with very high virologic failure rates. Further, 4-nRTI regimens are under investigation. The article summarizes a presentation on nRTIs made by Scott M. Hammer, MD, at the International AIDS Society-USA course in New York in March 2006. The original presentation is available as a Webcast at www.iasusa.org.</p>","PeriodicalId":85800,"journal":{"name":"Topics in HIV medicine : a publication of the International AIDS Society, USA","volume":"14 4","pages":"140-3"},"PeriodicalIF":0.0,"publicationDate":"2006-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26373064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Internet sex and dating sites need warnings.","authors":"Peter L Tenore","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>For this issue's Commentary column, Peter L. Tenore, MD, discusses risk for infection with HIV or acquisition of sexually transmitted diseases associated with the use of the Internet to find sexual partners and presents results of an informal survey to determine whether Internet sites used to find sexual partners provide warnings about sexually transmitted diseases and HIV. He also calls for the operators of such sites to add warnings to their sites.</p>","PeriodicalId":85800,"journal":{"name":"Topics in HIV medicine : a publication of the International AIDS Society, USA","volume":"14 4","pages":"146-7"},"PeriodicalIF":0.0,"publicationDate":"2006-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26373066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Eye of the needle.","authors":"David J Malebranche","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":85800,"journal":{"name":"Topics in HIV medicine : a publication of the International AIDS Society, USA","volume":"14 4","pages":"144-5"},"PeriodicalIF":0.0,"publicationDate":"2006-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26373068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Management of dyslipidemia and other cardiovascular risk factors in HIV-infected patients: case-based review.","authors":"Judith A Aberg","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Many HIV-infected patients have dyslipidemia and other cardiovascular risk factors prior to acquiring infection. Both HIV infection itself and antiretroviral therapy can cause or worsen lipid abnormalities. Management of dyslipidemia in the HIV-infected patient requires awareness of the effects of antiretroviral agents on lipid profiles, including potential sex- and race-related effects, and interactions between lipid-modifying agents and antiretroviral agents. This article uses individual case histories to illustrate the decisions encountered in treating HIV infection and dyslipidemia. The article is based on a presentation on management of dyslipidemia and other cardiovascular risk factors in HIV infection made by Judith A. Aberg, MD, at the International AIDS Society-USA Los Angeles CME program in February 2006.</p>","PeriodicalId":85800,"journal":{"name":"Topics in HIV medicine : a publication of the International AIDS Society, USA","volume":"14 4","pages":"134-9"},"PeriodicalIF":0.0,"publicationDate":"2006-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26373063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Structured treatment interruptions--new findings.","authors":"Constance A Benson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A number of recent studies have examined structured treatment interruption (STI) of antiretroviral therapy using CD4+ cell count-guided or time-based strategies in patients with chronic HIV infection and stable suppression of HIV RNA. On balance, data from these studies indicate that STI is associated with worse immunologic, virologic, and clinical outcomes than continuous antiretroviral therapy. However, the potential may still exist for use of short-term STI to manage drug toxicities in patients in this setting or to assess immunologic and virologic outcomes of novel interventions in carefully controlled clinical trials. This article summarizes a presentation on STI made by Constance A. Benson, MD, at the International AIDS Society-USA course in San Francisco in April 2006.</p>","PeriodicalId":85800,"journal":{"name":"Topics in HIV medicine : a publication of the International AIDS Society, USA","volume":"14 3","pages":"107-11"},"PeriodicalIF":0.0,"publicationDate":"2006-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26231897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}